Results of drug efficacy evaluation studies using the NASH model_Microbiome
Today, we would like to introduce to you a study published by our client, MRM Health, in which they used our pre-clinical services to evaluate their test article in our proprietary NASH model called STAMTM.
Title: A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo.
The above study tested the therapeutic effects of a defined bacterial consortium of nine gut commensal strains on NASH and fibrosis in our proprietary STAM™ model.
After oral administration of the consortium, the NAFLD Activity Score as well as the Sirius-red positive area (fibrosis) of the STAM mice showed a significant decrease compared to the vehicle group (Figure below; STAM+VEH vs STAM+CON).
The level of CK-18, which is a major NASH biomarker, was also decreased in the treatment group.
These results suggest that gut microbiome consortia have the potential to improve both NASH and fibrosis and can also delay disease progression.
Furthermore, this study successfully demonstrated that treatments improving the gut microbiome have the potential to be a useful therapeutic option for those suffering from NAFLD/NASH.
If you have a probiotic or prebiotic that is able to improve the gut microbiome or a compound that has a positive effect on bowel diseases, why not try it out in this model?
We will use our years of experience to provide you with a study design that will help you to successfully further your project.
Please feel free to contact us if you are interested in running a study in our STAMTM model.